1In July, 1998, the company was renamed as Beijing Shuanglu Pharmaceutical Co., Ltd., and in August, 2000, the company was restructured into a joint-stock company. In September 2004, Shuanglu Pharmaceutical (code 002038) was listed on Shenzhen Stock Exchange. Industry of China Securities Regulatory Commission: classified medicine and biological products.
Since its establishment, the company has always adhered to the corporate philosophy of survival by quality and development by innovation. In the past 10 years, 2 national first-class drugs and 8 national second-class drugs were developed and put on the market, all with independent intellectual property rights. At the same time, there are nearly 20 independent research and development countries, and the first and second class new drugs are in different stages of research and development or declared production from laboratory to clinical trial. In the next two years, dozens of new products will be put on the market one after another. Some R&D projects have won the first and second prizes of Beijing and national scientific and technological progress for many times.
1997, 2000 and 2002, the company applied as an independent enterprise for four times and was supported by the National 863 Program Fund, and two projects were supported by the National Technology Innovation Fund. 1996 10 was recognized as a high-tech enterprise by Beijing science and technology commission, and 1999 was listed as a key enterprise supported by Beijing and a key enterprise in the field of biopharmaceuticals. In 2000, 2003 and 2004, all dosage forms of the company passed the GMP certification of the State Administration of Pharmaceutical Products. In July 2000, it was recognized as a high-tech enterprise by the Ministry of Science and Technology and the Chinese Academy of Sciences (double-high recognition), and it is the industrialization base of four national 863 programs.
Due to the unclear medical reform in 2009 and fierce competition in the pharmaceutical industry, the market has doubts about whether Shuanglu Pharmaceutical can maintain high growth, which led to the weak trend in the fiery bull market in the first half of the year and was rated as the second in the top ten bear markets in 2009 by the market.
In addition to injection products, the data show that the compound coenzyme of Shuanglu Pharmaceutical Co., Ltd. shows a good growth trend. In the first three quarters, the company's sales revenue increased by nearly 50%, and its main revenue was 640 million, exceeding the total revenue of 620 million last year.
Our company is a joint stock limited company founded in June 2000 by four legal entities including Xinxiang Egret Chemical Fiber Group Co., Ltd. and five natural persons including Xu Mingbo. With the approval of China Securities Regulatory Commission, the company publicly issued A shares by way of offering, and listed on Shenzhen Stock Exchange on September 9, 2004.